Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Bayer151 enrolled

Overview

This study is a prospective, non-interventional, non-controlled, multi-center, observational cohort study. The medication is prescribed within the regular practice of the physician. Duration and dosage of treatment is solely at the discretion of the attending physician. The primary objective of this study is to assess duration of treatment in Turkish renal cell carcinoma patients treated with TKIs (Tyrosine Kinase Inhibitors) who could not tolerate prior cytokine treatment within the first month of treatment.

Study Type

OBSERVATIONAL

Enrollment

151

Conditions

Renal Cell Carcinoma

Interventions

No interventionOTHER

All dosage, frequency and duration for drugs will be under the decision of the treating physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * To be diagnosed as metastatic renal cell carcinoma * Previous cytokine therapy * To sign informed consent form (ICF) Exclusion Criteria: * Patients not willing to sign informed consent form or who withdraw their consent

Locations (1)

Unnamed facility

Many Locations, Turkey (Türkiye)

Outcomes

Primary Outcomes

Duration of treatment: from start of tyrosine kinase inhibitor treatment to permanent discontinuation of the product

Time frame: After 2 years

Secondary Outcomes

Incidence of treatment-emergent adverse events (TEAE)

Time frame: After 2 years

Change of Tumor status

Time frame: Baseline and 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.